<p class="abstract"><strong>Background:</strong> Acne vulgaris is chronic inflammatory disorder of pilosebaceous unit mainly characterized by comedones, papules and nodulocystic lesions affecting face and upper trunk. Topical dapsone 5% gel is approved to treat acne vulgaris because of its anti-inflammatory and anti-bacterial activities.</p><p class="abstract"><strong>Methods:</strong> A single center, open label interventional study was conducted during 1 year period in dermatology OPD of Jawaharlal Nehru Medical College, Sawangi (Meghe), Wardha, Maharashtra. Patients were enrolled in the study considering inclusion criteria. Patients were asked to apply dapsone 5% gel twice daily on face for 12 week. Efficacy was evaluated by mean percent reduction in total, inflammatory and non-inflammatory lesions and success rate on change in investigator global acne severity assessment scale while tolerability was assessed by evaluating skin dryness, erythema, stinging or burning sensation and scaling at baseline, 1, 2, 4, 8 and 12 week.<strong></strong></p><p class="abstract"><strong>Results:</strong> At end of 12 week, success rate reached to 31.54%. Dapsone 5% gel was effective in reduction of total, non-inflammatory and inflammatory lesions by 57.75%, 52% and 63.1% respectively. Side effects with dapsone gel were tolerable, mild and transient.</p><p><strong>Conclusions:</strong> Dapsone 5% gel was efficacious and well tolerated in non-inflammatory as well as inflammatory acne lesions. </p>